Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
November 17, 2023 09:04 ET
|
Altamira Therapeutics Ltd
Initiates Strategic Repositioning to Focus on Company’s Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue ...
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
November 10, 2023 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing...
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
September 14, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio® nasal spray in...
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
September 12, 2023 07:30 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical company...
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
September 06, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
August 23, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
July 20, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
July 17, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy-Study demonstrates statistically significant...
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
July 05, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue Altamira...
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
March 22, 2023 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Preprint of results from animal study shows restriction of tumor growth in mice treated with ZBTB46 mRNA nanoparticles based on Altamira’s...